Worldwide license agreement for ea1080, oral selective Α4Β7 integrin antagonist, signed between ea pharma and ensho therapeutics

Ensho acquired rights to develop and commercialize ea1080 and portfolio of other oral selective Α4Β7 integrin antagonists in all territories excluding japan, china, hong kong, macau, south korea, taiwan and asean ensho acquired rights to develop and commercialize ea1080 and portfolio of other oral selective Α4Β7 integrin antagonists in all territories excluding japan, china, hong kong, macau, south korea, taiwan and asean
EA Ratings Summary
EA Quant Ranking